» Articles » PMID: 6435454

Thyroid Gland Pigmentation and Minocycline Therapy

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 1984 Oct 1
PMID 6435454
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Thyroid pigments in black thyroid glands from minocycline-treated patients were compared by light and electron microscopy, histochemistry, and energy-dispersive x-ray analysis with minocycline-induced pigment in thyroid glands of laboratory animals, and with naturally occurring lipofuscins in untreated laboratory animals and humans. All thyroid samples examined contained nonbirefringent, Schmorl-positive pigment. However, the pigments in black thyroids from minocycline-treated patients resembled lipofuscins of untreated humans since both fluoresced and were Ziehl-Neelsen- and Sudan IV-positive. Minocycline induced pigment in rats was nonfluorescent and Ziehl-Neelsen- and Sudan IV-negative. Ultrastructurally, pigments in black thyroid glands of minocycline-treated humans resembled lipofuscins in untreated humans, and initial elemental analyses yielded similar spectra. Repeated analyses of the most electron-dense pigment deposits yielded spectra that resembled those of minocycline-induced pigment in laboratory animals-ie, both contained calcium. Black thyroid glands associated with minocycline administration contained predominantly lipofuscins with a small amount of another, possibly minocycline-related pigment. The absence of functional changes in patients and animals given minocycline suggests that discoloration of the thyroid gland associated with minocycline administration is innocuous. This is further supported by the lack of documented changes in thyroid physiology in patients that have received tetracyclines for a variety of indications in the last 30-odd years since their introduction to therapy.

Citing Articles

Minocycline-induced disruption of the intestinal FXR/FGF15 axis impairs osteogenesis in mice.

Carson M, Warner A, Hathaway-Schrader J, Geiser V, Kim J, Gerasco J JCI Insight. 2022; 8(1).

PMID: 36413391 PMC: 9870091. DOI: 10.1172/jci.insight.160578.


Black thyroid.

Bann D, Goyal N, Crist H, Goldenberg D Ear Nose Throat J. 2014; 93(10-11):E54-5.

PMID: 25397396 PMC: 4345646. DOI: 10.1177/014556131409310-1110.


Successful drug development despite adverse preclinical findings part 1: processes to address issues and most important findings.

Ettlin R, Kuroda J, Plassmann S, Prentice D J Toxicol Pathol. 2012; 23(4):189-211.

PMID: 22272031 PMC: 3234634. DOI: 10.1293/tox.23.189.


[Therapy related alterations to the thyroid gland].

Sheu S, Levin S, Schmid K Pathologe. 2006; 27(1):13-8.

PMID: 16402165 DOI: 10.1007/s00292-005-0813-y.


Black thyroid: report of an autopsy case.

Tsokos M, Schroder S Int J Legal Med. 2005; 120(3):157-9.

PMID: 16151826 DOI: 10.1007/s00414-005-0028-z.


References
1.
Heimann P . Ultrastructure of human thyroid. A study of normal thyroid, untreated and treated diffuse toxic goiter. Acta Endocrinol (Copenh). 1966; 53:Suppl 110:1+. View

2.
Becker K, Katz S, MIALE Jr A . Tetracycline and thyroid function. JAMA. 1967; 199(6):416-7. View

3.
BENITZ K, Roberts G, YUSA A . Morphologic effects of minocycline in laboratory animals. Toxicol Appl Pharmacol. 1967; 11(1):150-70. DOI: 10.1016/0041-008x(67)90035-x. View

4.
Borel D, Reddy J . Excessive lipofuscin accumulation in the thyroid gland in mucoviscidosis. Arch Pathol. 1973; 96(4):269-71. View

5.
Attwood H, Dennett X . A black thyroid and minocycline treatment. Br Med J. 1976; 2(6044):1109-10. PMC: 1689400. DOI: 10.1136/bmj.2.6044.1109. View